Seegene’s CURECA attracts attention at ESCMID Global 2025
Seegene Inc. presented a conceptual video of its CURECA at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) in Vienna, Austria.
Industry professionals recognized CURECA as a promising advancement in automating the entire PCR diagnostic workflow — from primary sample handling to result analysis. In response to the interest received, Seegene provided additional opportunities to showcase the solution at the ESCMID Global 2025.
More than 2,300 attendees — including dignitaries from Italy, Spain, Germany, France, and Canada — visited Seegene’s booth to view the conceptual video introducing the CURECA.
The CURECA is designed to automate the entire PCR diagnostic process. It can handle various specimen types required in the pre-treatment stage in MDx – such as stool, urine, blood, and sputum—as well as perform the complete PCR testing workflow following sample loading.
The first component of CURECA is the Customizable Pre-treatment System (CPS). The CPS is designed to automate the loading of primary sample tubes and operate pre-treatment processing.
For specimens that do not need preprocessing, Seegene offers the Primary Sample Aliquot System (PAS) as an alternative to the CPS. PAS is designed to allow direct loading and dispensing of primary samples, helping to simplify the workflow. Seegene is pursuing the integration of PAS with a fully automated PCR process through a modular solution concept called CEFA (Customizable & Expandable Full Automation), intended to support diverse laboratory needs with greater flexibility.
Seegene aims to leverage the modular architecture of CURECA to support a wide range of diagnostic applications.
Another key advantage of the CURECA’s modular architecture is that it is designed to adapt to different laboratory spaces and layouts. Its flexible design is intended to allow labs to configure the system according to their specific needs.
